A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling.
RNASET2
epithelial ovarian cancer
extracellular matrix
src family kinases
src kinase
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Feb 2019
22 Feb 2019
Historique:
received:
22
01
2019
revised:
18
02
2019
accepted:
20
02
2019
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
1
3
2019
Statut:
epublish
Résumé
RNASET2 is an extracellular ribonuclease endowed with a marked antitumorigenic role in several carcinomas, independent from its catalytic activity. Besides its antitumorigenic role by the recruitment to the tumor mass of immune cells from the monocyte/macrophage lineage, RNASET2 is induced by cellular stress and involved in actin cytoskeleton remodeling affecting cell interactions with the extracellular matrix (ECM). Here, we aimed to investigate the effects of RNASET2 expression modulation on cell phenotype and behavior in epithelial ovarian cancer (EOC) cellular models. In silico analysis on two publicly available datasets of gene expression from EOC patients (
Identifiants
pubmed: 30813308
pii: cancers11020255
doi: 10.3390/cancers11020255
pmc: PMC6406318
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG13055
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG17475
Organisme : Ministero della Salute
ID : RC20402
Organisme : Fondazione Cariplo
ID : 2013-0865
Organisme : Università degli Studi dell'Insubria
ID : FAR2017-2018
Références
Mol Biol Cell. 2000 Jan;11(1):51-64
pubmed: 10637290
Oncogene. 2001 Feb 22;20(8):980-8
pubmed: 11314033
Int J Oncol. 2005 May;26(5):1159-68
pubmed: 15809705
Am J Pathol. 2005 Nov;167(5):1411-27
pubmed: 16251425
Arch Biochem Biophys. 2006 May 15;449(1-2):17-26
pubmed: 16620762
Cancer Res. 2006 Sep 1;66(17):8633-9
pubmed: 16951177
Cancer. 2006 Dec 15;107(12):2760-9
pubmed: 17109444
Cancer Res. 2007 Jun 1;67(11):5258-66
pubmed: 17545605
Oncol Res. 2008;17(2):69-74
pubmed: 18543608
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
Med Mol Morphol. 2009 Jun;42(2):82-91
pubmed: 19536615
J Exp Med. 2009 Aug 3;206(8):1681-90
pubmed: 19635859
Br J Cancer. 2009 Nov 17;101(10):1699-708
pubmed: 19861960
Neoplasia. 2010 Aug;12(8):599-607
pubmed: 20689754
Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1104-9
pubmed: 21189302
Nat Med. 2011 Nov 20;17(12):1627-35
pubmed: 22101765
Oncogene. 2012 Sep 13;31(37):4139-49
pubmed: 22158046
Biol Cell. 2012 Jan;104(1):13-21
pubmed: 22188480
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
Mol Cell Biochem. 2013 Apr;376(1-2):73-9
pubmed: 23277333
Nat Rev Clin Oncol. 2013 Apr;10(4):211-24
pubmed: 23381004
Cancer Lett. 2013 Jul 28;335(2):259-69
pubmed: 23499893
Proc Natl Acad Sci U S A. 2013 May 14;110(20):8140-5
pubmed: 23630276
J Pathol. 2013 Sep;231(1):21-34
pubmed: 23780408
Nat Commun. 2013;4:2126
pubmed: 23839242
Cell Death Dis. 2014 Jan 23;5:e1022
pubmed: 24457966
PLoS One. 2014 Sep 17;9(9):e103988
pubmed: 25230021
Cancer Res. 2014 Dec 1;74(23):6980-90
pubmed: 25304260
Oncotarget. 2015 Apr 10;6(10):7851-65
pubmed: 25797262
Nat Rev Cancer. 2015 Apr;15(4):225-37
pubmed: 25801618
J Investig Dermatol Symp Proc. 2015 Jul;17(1):48-50
pubmed: 26067323
Cell Death Differ. 2016 Feb;23(2):347-57
pubmed: 26206090
Expert Opin Investig Drugs. 2016;25(1):15-30
pubmed: 26560712
Oncoscience. 2016 Mar 04;3(2):71-84
pubmed: 27014725
Gynecol Oncol. 2016 Aug;142(2):332-40
pubmed: 27235858
Int J Mol Sci. 2016 Aug 23;17(9):
pubmed: 27563880
Nat Rev Cancer. 2017 Jan;17(1):65-74
pubmed: 27885265
Ann Oncol. 2017 Nov 1;28(suppl_8):viii46-viii50
pubmed: 29232475
J Exp Clin Cancer Res. 2018 Jul 11;37(1):146
pubmed: 29996940
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Immunol Lett. 2018 Nov;203:102-111
pubmed: 30218741
Cancers (Basel). 2018 Nov 15;10(11):null
pubmed: 30445726